Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nevanac 3-Month Safety Study With QID Dosing

This study has been completed.
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: June 1, 2006
Last updated: March 1, 2012
Last verified: March 2012

The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.

Condition Intervention Phase
Drug: Nepafenac ophthalmic solution 0.1%
Drug: Ketorolac Tromethamine ophthalmic solution 0.4%
Other: Nepafenac ophthalmic suspension vehicle
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Macular thickness

Secondary Outcome Measures:
  • contrast sensitivity, corneal staining, VA, IOP, slit-lamp parameters, fundus parameters

Enrollment: 149
Study Start Date: February 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nevanac Drug: Nepafenac ophthalmic solution 0.1%
1 drop 4 times daily for 90 days
Active Comparator: Acular Drug: Ketorolac Tromethamine ophthalmic solution 0.4%
1 drop 4 times daily for 90 days
Placebo Comparator: Vehicle Other: Nepafenac ophthalmic suspension vehicle
Other Name: 1 drop 4 times daily for 14 days after surgery


Ages Eligible for Study:   10 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients of any race or sex ages 10 years or older undergoing cataract extraction with planned implantation of a posterior chamber intraocular lens.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Under 10
  • Other protocol-defined exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00332774

United States, Texas
Contact Alcon for Trial Locations
Fort Worth, Texas, United States, 76134
Sponsors and Collaborators
Alcon Research
Study Director: Stephen Lane Medical Monitor
  More Information

No publications provided

Responsible Party: Alcon Research Identifier: NCT00332774     History of Changes
Other Study ID Numbers: C-05-20
Study First Received: June 1, 2006
Last Updated: March 1, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Eye Diseases
Lens Diseases
Ketorolac Tromethamine
Ophthalmic Solutions
Pharmaceutical Solutions
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 20, 2014